Short answer
CATALYST PHARMACEUTICALS, INC. (CPRX) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 8.01 (Other Events). FTC granted early termination of the HSR waiting period on June 16, removing a key U.S. antitrust closing condition.
CATALYST PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FTC granted early termination of the HSR waiting period on June 16, removing a key U.S. antitrust closing condition
- Angelini Pharma’s planned acquisition of Catalyst remains subject to majority stockholder approval and other customary conditions
- Transaction expected to close in Q3 2026, leaving execution and timing risk for Catalyst shareholders
- Definitive proxy statement contains transaction terms, participant interests, and remaining deal risks requiring investor review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CATALYST PHARMACEUTICALS, INC. 8-K filings
Get the next CPRX 8-K as it lands
Follow CPRX for push alerts, or ask the research agent what this filing means.